目的研究MSCT血管重建和双重化疗栓塞治疗转移性肝癌的效果。
AIM: To study the effect of MSCT vascular reconstruction and chemoembolization through portal vein and liver artery in patients with liver cancer metastases.
结论用MSCT血管重建和肝动脉、门静脉双重化疗栓塞治疗转移性肝癌有一定临床效果，且无明显毒副作用。
CONCLUSION: Vascular restructure with MSCT and chemoembolization through portal vein and liver artery, with no obvious side-effects, are effective for patients with liver cancer metastases.
这种双重药物疗法抑制恶心与呕吐的最佳疗效时间为化疗后的24小时。
This two-drug regimen is most effective in preventing nausea and vomiting in the first 24 hours after chemotherapy.
目的探讨肝动脉、门静脉双重插管区域灌注化疗在中晚期不能切除原发性肝癌应用方法及临床疗效。
Objective To explore the curative effect of double intubated hepatic artery and portal vein regional infusion chemotherapy in non-resectable metaphase or late primary liver carcinoma.
结论中晚期不能切除的原发性肝癌使用肝动脉、门静脉双重插管灌注化疗，可以改善临床症状、延长存活期。
Conclusion Double intubated hepatic artery and portal vein regional infusion chemotherapy in non-resectable metaphase or late primary liver carcinoma may ameliorate symptoms and prolong survival time.
方法用碱性磷酸酶-抗碱性磷酸酶（APAAP）免疫酶标和DNA末端原位标记（ISEL）双重染色方法检测38例急性白血病诱导化疗前后骨髓涂片中细胞凋亡程度及细胞类型，初治组17例与2 1例经治病例对照。
Methods A double-stained way of APAAP and in situ DNA end labeling (ISEL) were used to detect apoptosis characteristics in 38 cases of acute leukemia, including 17 untreated and 21 treated patients.
方法用碱性磷酸酶-抗碱性磷酸酶（APAAP）免疫酶标和DNA末端原位标记（ISEL）双重染色方法检测38例急性白血病诱导化疗前后骨髓涂片中细胞凋亡程度及细胞类型，初治组17例与2 1例经治病例对照。
Methods A double-stained way of APAAP and in situ DNA end labeling (ISEL) were used to detect apoptosis characteristics in 38 cases of acute leukemia, including 17 untreated and 21 treated patients.
应用推荐